Incannex Healthcare (IXHL) Stock: Buy, Sell, or Hold?
IXHL - Incannex Healthcare Limited American Depositary Shares
$2.90
-0.20 (-6.45%)
▼
5d:
-9.66%
30d:
-11.04%
90d:
-8.52%
WAIT
LOW Confidence
Analysis Updated: Oct 12, 2026 12:00 AM ET
Earnings: Nov 13, 2026
30d
Get Alerted When IXHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: IXHL shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: IXHL shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: IXHL is currently trading at $2.90, which is considered oversold relative to its 30-day fair value range of $3.13 to $3.49. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.2) compared to its historical average (3.7). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, IXHL is in a uptrend. The price is currently testing key support at $2.85. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: IXHL scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.74 (+546.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, IXHL is in a uptrend. The price is currently testing key support at $2.85. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.5% recently.
Market Sentiment: IXHL scores 33/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $18.74 (+546.3%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$3.13 -
$3.49
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (33/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.5%)
- BULLISH: Trading 546.3% below Wall St target ($18.74)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$3.13 -
$3.49
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$2.85
Resistance Level
$3.35
Current Trend
Uptrend
Technical data as of
Oct 12, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.21
Wall Street Target
$18.74
(+546.3%)
Revenue Growth (YoY)
-100.0%
PE vs Historical
-1.2 vs 3.7
CHEAP
Share & Embed Analysis
Last updated: October 13, 2026 5:42 AM ET
Data refreshes hourly during market hours. Next update: 6:42 AM
Data refreshes hourly during market hours. Next update: 6:42 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IXHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 52 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 68 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 65 BUY |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$42 | 59 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
11 analysts |
$21 | 68 BUY |
